Vivos Therapeutics Inc. reported a 16% increase in full‑year 2025 revenue, reaching $17.4 million to $17.5 million from $15 million in 2024. The growth was driven by the integration of The Sleep Center of Nevada (SCN) and a strategic shift away from its legacy dentist‑centric model, which had been a drag on top‑line performance.
The company posted a net loss of $21.2 million, or $(2.07) per share, for the year. While revenue rose, operating expenses climbed as Vivos invested heavily in SCN’s integration and expanded its direct‑care network. Gross margin remained steady at 60%, but the wider operating loss reflects the upfront costs of scaling the new provider‑focused model.
Management highlighted that the new strategy has begun to generate higher contribution margins, although the overall operating loss widened. CEO Kirk Huntsman noted that the company is “on a clear path toward cash‑flow positive operations by the end of this year,” underscoring confidence in the long‑term viability of the pivot.
The earnings call, held on Thursday, April 15, 2026, also revealed that Vivos’ Q4 2025 EPS of –$0.46 beat analyst expectations of –$0.495, a beat of $0.035. The beat was attributed to stronger-than‑expected demand for sleep‑testing services and disciplined cost management amid the expansion of SCN.
Investors reacted positively to the results, with the stock gaining 0.88% in the open market and closing at $1.15. The market’s favorable response was driven by the revenue beat, the EPS beat, and the company’s clear guidance toward cash‑flow positivity, signaling confidence in the new business model despite the current net loss.
Vivos’ strategic pivot to a vertically integrated sleep‑care provider, anchored by SCN, is expected to drive higher‑margin revenue streams from diagnostic services and direct patient treatment. The company’s guidance for 2026 remains unchanged, but the management’s emphasis on cash‑flow positivity and the successful integration of SCN suggest a trajectory toward profitability as the new model matures.
The company’s financial health remains a concern, with a current ratio near 0.24 and a “Financial Strength” rating of 2/10. However, the 16% revenue growth and the steady gross margin indicate that the company is gaining traction in its new market focus, while ongoing investments are expected to narrow the operating loss over the next 12 to 18 months.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.